A SINGLE CENTER RETROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY BETWEEN LOW-DOSE VERSUS HIGH-DOSE RITUXIMAB AS REMISSION INDUCTION THERAPY IN JAPANESE PATIENTS WITH ANCA-ASSOCIATED VASCULITIS

被引:0
|
作者
Hirose, Kei [1 ]
Hirata, Manami [1 ]
Yamamura, Yuriko [1 ]
Ueno, Akiko [1 ]
Yamamura, Masahiro [1 ]
机构
[1] Okayama Saiseikai Gen Hosp, Ctr Rheumatol, Okayama, Japan
关键词
D O I
10.1136/annrheumdis-2019-eular.4450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AB0590
引用
收藏
页码:1756 / 1756
页数:1
相关论文
共 50 条
  • [21] Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis
    Miloslavsky, Eli
    Specks, Ulrich
    Merkel, Peter A.
    Seo, Philip
    Spiera, Robert F.
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    St Clair, E. William
    Tchao, Nadia
    Ding, Linna
    Ikle, David
    Jepson, Brett
    Brunetta, Paul
    Stone, John H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S313 - S313
  • [22] Reduced-dose vs high-dose glucocorticoids added to rituximab and remission induction in ANCA-associated vasculitis (vol 326, pg 1536, 2021)
    Jayne, D. R. W.
    Merkel, P. A.
    Bekker, P.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (17): : 1697 - 1697
  • [23] Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
    Tamaki, Hiromichi
    Butler, Robert
    Langford, Carol A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [24] Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study
    Furuta, Shunsuke
    Nakagomi, Daiki
    Kobayashi, Yoshihisa
    Hiraguri, Masaki
    Sugiyama, Takao
    Amano, Koichi
    Umibe, Takeshi
    Kono, Hajime
    Kurasawa, Kazuhiro
    Kita, Yasuhiko
    Matsumura, Ryutaro
    Kaneko, Yuko
    Ninagawa, Keita
    Hiromura, Keiju
    Kagami, Shin-ichiro
    Inaba, Yosuke
    Hanaoka, Hideki
    Ikeda, Kei
    Nakajima, Hiroshi
    LoVAS collaborators
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (01) : 96 - 102
  • [25] THE UTILITY OF LOW DOSE RITUXIMAB FOR INDUCTION AND MAINTENANCE TREATMENT IN ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS: A SINGLE CENTRE EXPERIENCE
    Metraiah, El Hakem
    Dospinescu, Paula
    Fluck, Nicholas
    Basu, Neil
    Kidder, Dana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 688 - 688
  • [26] A LOW DOSE GLUCOCORTICOID, LOW DOSE CYCLOPHOSPHAMIDE, RITUXIMAB TREATMENT PROTOCOL AS INDUCTION THERAPY IN ANCA ASSOCIATED VASCULITIS PATIENTS
    Spanos, Georgios
    Paschou, Styliani
    Bakou, Marianna
    Atalla, Alexandros
    Bantis, Christos
    Fragidis, Stylianos
    Armetzoiou, Livia Karmen
    Bamichas, Gerasimos
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I405 - I406
  • [27] LONG-TERM FOLLOW-UP OF A COMBINED RITUXIMAB AND LOW-DOSE CYCLOPHOSPHAMIDE REGIMEN FOR REMISSION INDUCTION IN RENAL ANCA-ASSOCIATED VASCULITIS
    McAdoo, Stephen Paul
    Gopaluni, Seerapani
    Medjeral-Thomas, Nicholas
    Tanna, Anisha
    Griffith, Megan
    Levy, Jeremy
    Cook, Terence
    Cairns, Thomas
    Salama, Alan
    Jayne, David
    Pusey, Charles
    RHEUMATOLOGY, 2017, 56 : 153 - 153
  • [29] Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis
    Nagafuchi, Hiroko
    Atsumi, Tatsuya
    Hatta, Kazuhiro
    Muso, Eri
    Takeno, Mitsuhiro
    Yamada, Hidehiro
    Ozaki, Shoichi
    MODERN RHEUMATOLOGY, 2015, 25 (04) : 603 - 608
  • [30] A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE
    Smith, R.
    Jayne, D.
    Merkel, P. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 19 - 20